

Contents

List of Contributors XVII

Foreword XXIII

Timeline XXVII

Introduction XXIX

Preface XXXV

- 1 Determinants of Phagocytosis, Phagosome Biogenesis and Autophagy for *Mycobacterium tuberculosis*** 1
Larry S. Schlesinger, Abul K. Azad, Jordi B. Torrelles, Esteban Roberts, Isabelle Vergne, and Vojo Deretic
- 1.1 Introduction 1
- 1.2 Mycobacterial Determinants in Host Recognition: Example of Host Adaptation 1
- 1.3 Hierarchy of Host Receptors: Importance of the Lung Environment 3
- 1.4 Other Macrophage Receptors for *M. tuberculosis* 4
- 1.5 Relationship Between Route of Entry and Survival for *M. tuberculosis* 5
- 1.6 Host Intracellular Trafficking Regulators and Phago-Lysosome Biogenesis 9
- 1.7 Rabs and Rab Effectors Affected by *M. tuberculosis* 10
- 1.8 Host Lipids Affected by *M. tuberculosis* 11
- 1.9 Mycobacterial Products Affecting Phago-Lysosome Biogenesis 11
- 1.10 Induction of Autophagy Overcomes *M. tuberculosis* Phagosome Maturation Block and Kills Intracellular Mycobacteria 12
- References 14
- 2 Dendritic Cells Inflammatory Signature Induced by Microbial Pathogens** 23
Maria Foti, Ottavio Beretta, Mattia Pelizzola, Paola Ricciardi-Castagnoli
- 2.1 Introduction 23
- 2.2 DC Biology and Function 24
- 2.3 Microbial Infections and DC Responses 25
- 2.4 DCs in Anti-Mycobacterial Responses 28

2.5	Inflammation and its Regulation	29
2.6	Bacterial Signaling via TLRs	30
2.7	Bacteria–Host and Mycobacteria–Host Interactions: A Genome-Wide Approach	32
2.8	Genome-Wide Studies to Dissect DC Inflammatory Signatures	35
2.9	Conclusions	36
	References	37
3	<i>Mycobacterium tuberculosis</i> Interactions with Dendritic Cells and Macrophages	45
	<i>Padmini Salgame, Kamlesh Bhatt, Michael G. Drage, Nicole D. Pecora, Clifford V. Harding</i>	
3.1	Introduction	45
3.2	Interactions of <i>M. tuberculosis</i> with Innate Receptors on APCs	46
3.3	Transport of <i>M. tuberculosis</i> to DLNs for Priming	47
3.4	Cytokine Secretion, Costimulation and Antigen Presentation	49
3.5	TLR Ligands Expressed by <i>M. tuberculosis</i> , Particularly TLR2	51
3.6	TLR2-Mediated Exploitation of APC Function by <i>M. tuberculosis</i>	52
3.7	Conclusions	53
	References	53
4	Killing Mechanisms of the Host Against <i>Mycobacterium tuberculosis</i>	61
	<i>Paul J. Maglione, John Chan</i>	
4.1	Introduction	61
4.2	Macrophages: An Important Component of the Cellular Immune Response in Host Defense Against <i>M. tuberculosis</i>	63
4.3	Macrophages Require Activation for Optimal Microbial Killing	64
4.4	Reactive Nitrogen and Oxygen Intermediates in Host Defense Against Tuberculosis	66
4.5	Phago-Lysosome Biogenesis in <i>M. tuberculosis</i> Killing	70
4.6	The IFN γ –LRG-47 Pathway and the Role of Autophagy in Defense Against <i>M. tuberculosis</i>	71
4.7	Sunlight and Anti-microbial Peptides: Key Components for Innate Immunity Against <i>M. tuberculosis</i>	73
4.8	Apoptosis as a Killing Mechanism of <i>M. tuberculosis</i>	75
4.9	Infection Equilibrium and the Relativity of <i>M. tuberculosis</i> Killing	76
4.10	Conclusions	77
	References	78
5	Manipulation of the Macrophage Response by Pathogenic <i>Mycobacteria</i>	91
	<i>Jean Pieters</i>	
5.1	Introduction	91

5.2	The Macrophage	91
5.3	Internalization of <i>M. tuberculosis</i> in Macrophages	92
5.3.1	Complement Receptors	94
5.3.2	Mannose Receptor	95
5.3.3	Cholesterol	96
5.3.4	Surfactants	96
5.3.5	Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin	96
5.4	The Mycobacterial Phagosome	97
5.4.1	Modulation of the Mycobacterial Phagosome – Host Factors	97
5.4.1.1	Coronin 1	98
5.4.1.2	Immunity-Related GTPases	100
5.4.2	Modulation of the Mycobacterial Phagosome – Mycobacterial Factors	100
5.4.2.1	Mycobacterial Glycolipids	101
5.4.2.2	Exported Repetitive Protein (Erp)	101
5.4.2.3	Isocitrate Lyase	102
5.4.2.4	Mycobacterial Phosphatase SapM	102
5.4.2.5	Mycobacterial Protein Kinase G	102
5.5	Interference with Antigen Processing and Presentation Functions	103
5.6	Subversion of Macrophage Activation and Signal Transduction	105
5.6.1	Reactive Oxygen and Nitrogen Intermediates and the Mycobacterial Proteasome	105
5.6.2	IFN- γ , TNF- α and Phagosome–Lysosome Fusion	106
5.6.3	Macrophage Activation and Mycobacterial LAM	106
5.6.4	TLRs and Macrophage Activation	106
5.6.5	Mammalian Cell Entry Proteins	107
5.6.6	Intracellular Pathogen Resistance Gene	107
5.7	Conclusions	108
	References	108
6	Human CD4 and CD8 T Cell Responses to <i>Mycobacterium tuberculosis</i>: Antigen Specificity, Function, Implications and Applications	119
	<i>Tom H.M. Ottenhoff, Deborah A. Lewinsohn, David M. Lewinsohn</i>	
6.1	Introduction	119
6.2	Human CD4 ⁺ T Cells, Cytokines and Resistance to Mycobacterial Infections, Including Tuberculosis	121
6.3	CD4 ⁺ T Cell Subsets in Human Tuberculosis	122
6.3.1	T _h 1 Cells	122
6.3.2	T _h 2 Cells	123
6.3.3	T _r Cells, Including T _h 3 Cells	123
6.4	The <i>M. tuberculosis</i> Antigen Repertoire Recognized by CD4 ⁺ T Cells in Humans	125

- 6.4.1 Mycobacterial Heat Shock Proteins Conservation Breeds Immunodominance 125
- 6.4.2 The *M. tuberculosis* Secretome – A Rich Source of Immunodominant Antigens for Human T Cells 125
- 6.4.3 Antigen Discovery: Genome and Proteome Based Approaches Lead to the Identification of New Families of Antigenic Targets 127
 - 6.4.3.1 ESAT-6, PE and PPE Superfamilies 127
 - 6.4.3.2 Additional Antigen Discovery Strategies 128
 - 6.4.3.3 Towards a Comprehensive and Integrated *M. tuberculosis* Antigenomics Database 128
 - 6.4.3.4 Post-Translational Modification of *M. tuberculosis* Proteins Can Create New Antigenic Determinants for CD4⁺ T Cells 129
 - 6.4.3.5 New Classes of ‘Post-Genomic Antigens’: Towards the Discovery of Phase/ Stage-Specific *M. tuberculosis* Antigens and Phase/Stage-Specific Vaccines? 129
 - 6.4.3.6 Phase-Specific Antigen Profiles of *M. tuberculosis*: Do Starvation and Reactivation Antigens Exist? 130
- 6.5 The Contribution of CD8⁺ T Cells to Protective TB Immunity: The Mouse Model 130
- 6.6 CD8⁺ T Cells in Human TB 131
- 6.7 Redundant Functions of CD8⁺ and CD4⁺ T Cells in TB Protection 132
- 6.8 Unique Role for CD8⁺ T Cells in TB Protection 133
- 6.9 Model of TB Reactivation Based upon T Cell Function 133
- 6.10 CD8 Antigen Processing and Presentation 134
- 6.11 The CD8 Antigenic Repertoire and Immunodominance 135
 - 6.11.1 CD8 Epitopes Processed and Presented by *M. tuberculosis*-Infected Cells 135
 - 6.11.2 Identification of Immunodominant CD8 Antigens and Epitopes 137
 - 6.11.3 CD8 Antigenic Repertoire Summary 137
 - 6.11.3.1 The Vast Majority of Defined CD8 Epitopes are Restricted by HLA-B Alleles 137
 - 6.11.3.2 Many Immunodominant Epitopes are Longer than 9 Amino Acids and May Not Have Been Identified Using Current Bioinformatic Tools 138
 - 6.11.3.3 CFP-10 is an Immundominant CD8 Antigen 138
 - 6.12 Compartmentalization of *M. tuberculosis*-Specific T Cell Responses in Human TB 138
 - 6.13 Immunodominance and Chronic Infection with *M. tuberculosis* 139
 - 6.14 Future Outlook: What do we Know, What do we Need to Know, and How can Immunology Translate into Better Diagnostics, Vaccines and Biomarkers? 140
 - 6.14.1 Improved Immunodiagnosics, Based on *M. tuberculosis*-Specific T Cell Recognition Profiles 140
 - 6.14.2 *M. tuberculosis* Stage-Specific Vaccines 141

6.14.3	Identification of <i>M. tuberculosis</i> Antigens that Selectively Induce a T Cell Phenotype	141
6.14.4	Identification of Improved Human Correlates of Protection and Disease	142
	References	143
7	Unconventional T Cells	157
	<i>S.M. Behar, W.H. Boom</i>	
7.1	Introduction	157
7.2	CD1-Restricted T Cell Responses in <i>M. tuberculosis</i> and <i>M. leprae</i> Infection	157
7.2.1	Introduction to CD1-Restricted T Cells	157
7.2.2	Group I CD1-Restricted T Cell Responses	158
7.2.2.1	Regulation of Group I CD1 by <i>M. tuberculosis</i> and Toll-Like Receptor Ligands	158
7.2.2.2	Recognition of Mycobacterial Lipid Antigens by T Cells	159
7.2.2.3	CD1-restricted T Cells Recognize Infected Cells	160
7.2.2.4	Intracellular Trafficking of the Different CD1 Isoforms	160
7.2.2.5	Effector Functions of Mycobacteria-Specific CD1-Restricted T Cells	161
7.2.2.6	Frequency and Distribution of CD1-Restricted Mycobacteria Specific T Cells in Infections	161
7.2.2.7	Animal Models of CD1-Restricted T Cells in Mycobacterial Infection	162
7.2.3	Group II CD1-Restricted T Cell Responses in <i>M. tuberculosis</i>	162
7.2.3.1	Regulation of CD1d by <i>M. tuberculosis</i> and TLR Ligands	162
7.2.3.2	Recognition of Mycobacterial Lipid Antigens by CD1d-Restricted T Cells	163
7.2.3.3	Antigen-Independent Activation of CD1d-Restricted T Cells	163
7.2.3.4	Relevant Effector Functions of CD1d-Restricted <i>Mycobacterium</i> -Specific T Cells	164
7.2.3.5	The Role of CD1d-Restricted NKT Cells in Host Resistance to TB	165
7.3	$\gamma\delta$ T Cells and <i>M. tuberculosis</i>	166
7.3.1	General $\gamma\delta$ T Cell Biology	166
7.3.1.1	$\gamma\delta$ TCR and $\gamma\delta$ T Cell Development?	167
7.3.1.2	$\gamma\delta$ T Cell Phenotype and Function	168
7.3.2	$\gamma\delta$ T Cell Antigens and Response to <i>M. tuberculosis</i>	168
7.3.2.1	Recognition of Phosphoantigens by Human $V_\gamma 9/V_\delta 2$ T Cells	169
7.3.2.2	Human $V_\gamma 9/V_\delta 2$ T Cell Responses to <i>M. tuberculosis</i>	170
7.3.3	$\gamma\delta$ T Cells in Animal Models of <i>M. tuberculosis</i> Infection	171
7.3.3.1	$\gamma\delta$ T Cells and Murine <i>M. tuberculosis</i> Infection	171
7.3.3.2	$\gamma\delta$ T Cells and Mycobacterial Infection in Primates	172
7.4	Other Non-conventional T Cells: $CD25^+CD4^+ T_b$, IL-17-Producing $CD4^+$ T Cells (T_H17), HLA-E-Restricted $CD8^+$ T Cells and H2-M3-Restricted T Cells	173

7.4.1	T _r Cells	173
7.4.2	T _h 17	173
7.4.3	HLA-E-Restricted CD8 ⁺ T Cells and H2-M3-Restricted T Cells	174
7.5	Conclusions	175
	References	175

8 Cytokines in Tuberculosis 185

Anne O'Garra, Warwick J. Britton

8.1	Introduction	185
8.2	General Introduction to Cytokines in the Immune Response	185
8.2.1	Cytokines in the Innate Immune Response	185
8.2.1.1	Differential Expression of Toll-Like Receptors Determines the Production of Cytokines by Macrophages and DCs	186
8.2.1.2	Intrinsic Capacity of Macrophages and DCs to Produce Different Cytokines	186
8.2.2	Cytokines in the Development of the Adaptive T Cell Response to Pathogens	187
8.2.2.1	Induction of T _h 1 and T _h 2 Responses and their Role in Infectious Diseases	187
8.2.2.2	The T _h 17 Response: Relationship with IL-23 and TGF-β	187
8.2.3	Role of IL-10 and Other Factors in Regulating Immune Responses to Pathogens	190
8.3	Cytokines in Innate and Adaptive Immunity to <i>M. tuberculosis</i>	191
8.3.1	T _h 1 T Cell Responses are Required for Protective Anti-Mycobacterial Responses	191
8.3.2	IFN-γ/IL-12 Axis and Mendelian Susceptibility to Mycobacterial Diseases	193
8.3.3	Production of IFN-γ During Active Tuberculosis	194
8.3.4	Depression of IFN-γ Responses in PBMCs from Active TB Patients	194
8.3.5	Suppressive Cytokines in Mycobacterial Infections	195
8.3.6	T _h 2 Cytokines and Tuberculosis	197
8.4	Effector Cytokines for Macrophage Activation and Regulation	198
8.4.1	IFN-γ	198
8.4.2	Other Cytokines Contributing to Macrophage Activation	201
8.5	Cytokines Required for Granuloma Formation	203
8.5.1	TNF Family Members	203
8.5.2	Chemokines and Granuloma Formation	205
8.6	Conclusions	206
	References	206

9 The Antibody Response to Infection with *Mycobacterium tuberculosis* 227

Graham Bothamley, Maria Laura Gennaro

9.1	Humoral Immunity and Tuberculosis	227
9.2	The Course of the Antibody Response	228

9.2.1	Natural Antibodies	230
9.2.2	T-Independent B Cell Responses	230
9.2.3	Latent Infection and Early Disease	232
9.2.4	Active Disease	232
9.2.5	Treatment	233
9.3	Antigen Specificity of The Antibody Response and Life Cycle of the Tubercle Bacillus	234
9.3.1	Antigen Production in Dormant <i>M. tuberculosis</i>	234
9.3.2	Antigen Production in Rapidly Dividing <i>M. tuberculosis</i>	235
9.3.3	Sources of Variation in Antibody Specificity: The Pathogen	236
9.3.3.1	Concurrent Bacterial Subpopulations	236
9.3.3.2	The Granuloma	236
9.3.3.3	Strain-Specific Differences	236
9.3.4	Sources of Variation in Antibody Specificity: The Human Host	237
9.3.4.1	Spectrum of Disease	237
9.3.4.2	Host Genetics	237
9.4	Antibodies and Pathogenesis	237
9.5	Antibodies and Diagnosis	238
9.6	Conclusions	239
	References	239
10	Immunopathology of Tuberculosis	245
	<i>Bernadette M. Saunders, Ian M. Orme, Randall J. Basaraba</i>	
10.1	Introduction	245
10.1.1	Historical Perspective	245
10.1.2	Koch Phenomenon	246
10.1.3	Pathology of TB	246
10.2	Granuloma Development	247
10.2.1	The Immunopathology of TB Infection in Mice	247
10.2.2	Granuloma Development in Humans	249
10.2.3	Pathology of Early and Late Disease Progressors	250
10.2.4	Cellular and Cytokine Requirements for Granuloma Development	251
10.2.4.1	T Cells	251
10.2.4.2	Macrophages and DCs	251
10.2.4.3	B Cells	252
10.2.4.4	Cytokine Requirements for Granuloma Formation	252
10.2.4.5	Chemokine Requirements	256
10.3	Pathology of TB in Guinea Pigs Compared to Humans	257
10.3.1	Introduction	257
10.3.1.1	Course of the Infection in Guinea Pigs Exposed to Aerosol Infection	257
10.3.2	The Primary Lesion Complex	258
10.3.2.1	Pathology of Primary Pulmonary Lesions	258
10.3.2.2	Pathogenesis of Primary Pulmonary Lesions	259
10.3.2.3	Pathogenesis of Primary Lesion Necrosis	262

10.3.2.4	Hypoxia of Primary Lesions	263
10.3.2.5.	<i>M. tuberculosis</i> -Derived Mediators of Inflammation	263
10.3.3	Chronic Infection	263
10.3.3.1	Iron Accumulation in Primary Lesions	263
10.3.3.2	Dystrophic Calcification of Primary Lesions	264
10.3.3.3	Pathology of Primary Lymph Node Lesions	264
10.3.3.4	Pathogenesis of Secondary Lesions	266
10.3.3.5	Pathogenesis of Extrapulmonary Lesions	267
10.3.3.6	Dissemination as a Determinate of Virulence	267
10.3.4	Pathology of the Primary Lesion Complex in the BCG Vaccinated Guinea Pig	268
10.3.5	Pathology of the Primary Lesion Complex in the Drug-Treated Guinea Pig	269
10.3.6	Alternative Methods for Lesion Evaluation in the Guinea Pig	269
	References	270

11 Maintenance of Latent Infection, with Correlates of Protective Immunity 279

Willem A. Hanekom, Joel D. Ernst

11.1	Definition and Evidence of Latency in Tuberculosis	279
11.2	Relative Contribution of Reactivation and New Infections	281
11.2.1	Evidence that Newly Transmitted TB Contributes to the Burden of Disease in Adults	281
11.2.2	Evidence that Reinfection with <i>M. tuberculosis</i> Contributes to Recurrent TB in Adults who have Completed Therapy for Active TB	282
11.3	Epidemiologic Risk Factors for Reactivation of Latent TB Infection	282
11.4	Mechanisms of Latency and Protective Immunity in TB	283
11.4.1	Bacterial Determinants of Establishment and Maintenance of Latency	283
11.4.2	Host Determinants of Maintenance of Latency	285
11.4.2.1	CD4 ⁺ T Lymphocytes	285
11.4.2.2	TNF (Tumor Necrosis Factor)	286
11.4.2.3	Correlates of Immunity and Latency Identified by Studies of Human Genetics	287
11.5	Vaccination-Induced Immune Correlates of Protection	287
11.5.1	Evidence from Animal Models	287
11.5.2	Human Studies of Vaccination-Induced Immune Correlates of Protection	292
11.6	Directions for Further Study	294
	References	295

12 Genetic Control of Host Susceptibility to Tuberculosis 305

Erwin Schurr, Igor Kramnik

12.1	Introduction: The Aspects of Tuberculosis – General Categories	305
------	--	-----

12.2	Genetic Analysis of TB Susceptibility Using Experimental Animal Models	306
12.3	Mouse Model of TB Infection: The Genetic Perspective	307
12.3.1	Natural Genetic Variation in the Laboratory Mice Allows Modeling Major Aspects of the Human Disease	308
12.3.2	Genetic Control of Host Resistance to TB Infection in the Mouse Model is Complex	311
12.3.3	Characterization of the Individual TB Resistance loci	313
12.3.3.1	Chromosome 17	313
12.3.3.2	Chromosome 7 Locus	314
12.3.3.3	The Chromosome 1 Loci: <i>Bcg</i> / <i>Ity</i> / <i>Lsh</i> (<i>Nramp1</i> Gene) and <i>sst1</i> (<i>Ipr1</i> Gene)	315
12.3.3.4	The <i>Bcg</i> Locus and the <i>Nramp1</i> Gene	315
12.3.3.5	The <i>sst1</i> Locus and the <i>Ipr1</i> Gene	317
12.3.4	Summary of the Experimental Genetic Analysis in Mice and Future Directions	319
12.4	The Genetic Spectrum of TB in Humans: From Mendelian Disease to Polygenic Trait	319
12.5	Strategies for the Molecular Identification of Alleles that Cause Increased Susceptibility to TB Disease	321
12.6	Gene Hunting: MSMD in TB	323
12.7	Gene Hunting: Major Susceptibility Genes in TB	324
12.8	Gene Hunting by Candidate Gene Studies: Polygenic Susceptibility in TB	326
12.8.1	HLA Class II loci	327
12.8.2	Cytokines and Their Receptors	327
12.8.3	Vitamin D Receptor	328
12.8.4	Toll-Like Receptors, their Signaling Pathways and Other Innate Immunity Genes	329
12.8.5	Additional Innate Immunity Genes	330
12.8.6	Candidate Genes Obtained from Mouse Studies: <i>NRAMP1</i> and <i>SP110</i>	331
12.8.7	Genetic Control of Immune Responsiveness to Mycobacterial Antigens	333
12.9	Conclusions	333
	References	333
13	Tuberculosis/Human Immunodeficiency Virus Coinfection and the Host Immune Response	347
	<i>Anne E. Goldfeld, Shahin Ranjbar, Erdyni N. Tsitsikov</i>	
13.1	The Problem	347
13.2	Why is the Combination of TB and HIV-1 So Deadly?	349
13.3	TB/HIV-1 Coinfection Targets CD4 T Cells	351
13.4	Mononuclear Phagocytes: A Home for Both TB and HIV-1	355
13.5	HAART in TB/HIV-1 Coinfection	357

13.6	PR in TB/HIV-1: A Clue to Immunopathogenesis of Coinfection	358
13.7	Conclusion	359
	References	359
14	Novel Vaccination Strategies Against Tuberculosis	369
	<i>Peter Andersen, Stefan H.E. Kaufmann</i>	
14.1	Introduction	369
14.2	Host Resistance, Latency and TB	370
14.3	The Two Major Vaccination Strategies Against TB	371
14.4	Attenuated Gene Deletion Mutants of <i>M. tuberculosis</i> as Vaccine Candidates	372
14.5	Improved Recombinant BCG as Vaccine Candidates (Table 14.1)	373
14.6	Subunit Vaccines (Table 14.1)	375
14.7	Boosting or Supplementing Immunity Induced by BCG Prime	377
14.8	Vaccine Strategies to Target Latent Infection	379
14.9	Entering the Clinic	382
14.10	Exploiting Biomarkers for Vaccine Trials?	383
14.11	Economic Considerations	384
	References	384
15	Experimental Animal Models of Tuberculosis	389
	<i>JoAnne L. Flynn, Liana Tsenova, Angelo Izzo, Gilla Kaplan</i>	
15.1	Introduction	389
15.2	Murine Model of TB	390
15.2.1	Mouse and Bacterial Strains Used	390
15.2.2	Course of Infection in Mice	390
15.2.2.1	Route of Infection	390
15.2.2.2	Dynamics of Infection and Disease	391
15.2.3	Pathology	393
15.2.4	Uses of the Model	394
15.2.4.1	Immunology and Host Response	394
15.2.4.2	Pathogenesis	395
15.2.4.3	Drug development and Testing	396
15.2.4.4	Vaccine Development and Testing	396
15.3	The Guinea Pig Model	397
15.3.1	Strains of Guinea Pigs	397
15.3.2	Infection and Course of Disease	397
15.3.3	Immunologic Studies	398
15.3.4	Uses of the Model: Vaccine Testing	399
15.3.5	Pathology	399
15.3.6	Advantages and Limitations	401
15.4	The Rabbit Model	401
15.4.1	Rabbit and Mycobacterial Species	401
15.4.2	Uses of the Model	402

15.4.2.1	Experimental TBM	402
15.4.2.2	Experimental Pulmonary TB	405
15.5	The Non-human Primate Model	408
15.5.1	Non-human Primate and Mycobacterial Species	408
15.5.2	Course of Infection and Disease	409
15.5.3	Pathology	410
15.5.4	Uses of the Model	413
15.5.4.1	Immunology	413
15.5.4.2	Pathogenesis	413
15.5.4.3	Drug Testing	414
15.5.4.4	Vaccine Testing	414
15.5.4.5	A Model for AIDS and TB	414
15.5.5	Limitations to the Non-human Primate Model	415
15.6	Other Animal Model Systems	416
15.7	Conclusions	416
	References	417

Index	427
--------------	-----

